Equities Analysts Offer Predictions for Chiasma Inc’s FY2019 Earnings (NASDAQ:CHMA)

Chiasma Inc (NASDAQ:CHMA) – Equities researchers at Cantor Fitzgerald boosted their FY2019 EPS estimates for shares of Chiasma in a research report issued on Wednesday, November 6th. Cantor Fitzgerald analyst B. Folkes now anticipates that the biotechnology company will earn ($1.08) per share for the year, up from their prior forecast of ($1.09). Cantor Fitzgerald currently has a “Buy” rating and a $18.00 target price on the stock.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.01.

CHMA has been the subject of a number of other reports. Piper Jaffray Companies started coverage on shares of Chiasma in a research report on Wednesday, July 31st. They issued an “overweight” rating and a $11.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chiasma in a research report on Thursday. ValuEngine downgraded shares of Chiasma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Chiasma from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. Finally, Brookline Capital Management reissued a “buy” rating on shares of Chiasma in a research report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $12.30.

Shares of CHMA stock opened at $5.25 on Friday. Chiasma has a 52-week low of $2.11 and a 52-week high of $9.25. The company has a 50-day simple moving average of $5.13 and a two-hundred day simple moving average of $5.95. The company has a market capitalization of $225.72 million, a price-to-earnings ratio of -4.10 and a beta of 1.19.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new position in Chiasma in the 3rd quarter worth approximately $53,000. Tower Research Capital LLC TRC boosted its holdings in Chiasma by 461.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 14,938 shares of the biotechnology company’s stock worth $74,000 after buying an additional 12,277 shares during the period. Clear Harbor Asset Management LLC bought a new position in Chiasma in the 3rd quarter worth approximately $83,000. Quantitative Systematic Strategies LLC bought a new position in Chiasma in the 2nd quarter worth approximately $100,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in Chiasma by 35.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,722 shares during the period. 53.00% of the stock is owned by institutional investors.

In other news, Director Roni Mamluk sold 50,000 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $5.59, for a total transaction of $279,500.00. Following the completion of the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $279,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Scott Minick bought 9,818 shares of Chiasma stock in a transaction dated Tuesday, August 20th. The shares were bought at an average cost of $5.19 per share, with a total value of $50,955.42. Following the completion of the transaction, the director now directly owns 62,531 shares in the company, valued at $324,535.89. The disclosure for this purchase can be found here. Insiders have bought a total of 17,268 shares of company stock valued at $96,823 over the last three months. Insiders own 8.30% of the company’s stock.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Earnings History and Estimates for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.